Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

Tashima, Karen; Crofoot, Gordon; Tomaka, Frank L.; Kakuda, Thomas N.; Brochot, Anne; van de Casteele, Tom; Opsomer, Magda; Garner, William; Margot, Nicolas; Custodio, Joseph M.; Fordyce, Marshall W.; Szwarcberg, Javier
December 2014
AIDS Research & Therapy;2014, Vol. 11, p1
Academic Journal
Background Cobicistat is an alternative pharmacoenhancer to ritonavir. In healthy volunteers, darunavir exposure was comparable when darunavir 800 mg once-daily was co-administered with cobicistat 150 mg once-daily (as single agents or a fixed-dose combination) vs. with ritonavir 100 mg once daily. Methods This 48-week, Phase IIIb, single-arm, US multicenter study (NCT01440569) evaluated safety, efficacy and pharmacokinetics of darunavir/cobicistat 800/150 mg once daily (as single agents) plus two investigator-selected nucleoside/tide reverse transcriptase inhibitors (N[t]RTIs) in HIV-1-infected adults. Patients had no darunavir resistance-associated mutations (RAMs), plasma viral load (VL) ≥1000 HIV-1 RNA copies/ml, eGFR ≥80 ml/min and genotypic sensitivity to the two N[t]RTIs. The primary endpoint was any treatment- emergent grade 3 or 4 adverse events (AEs) through Week 24. Results The majority of the 313 intent-to-treat patients were treatment-naïve (295/313; 94%), male (89%), White (60%) and received a tenofovir-based regimen (99%). Median baseline VL and CD4+ count overall were 4.8 log10 HIV-1 RNA copies/ml and 361 cells/mm³, respectively. Overall, 86% of patients (268/313) completed the study. The majority of discontinuations were for AEs (15/313; 5%). The incidence of treatment-emergent grade 3 or 4 AEs regardless of causality was 6% through Week 24 and 8% through Week 48. Most common AEs through Week 48 were diarrhea (27%) and nausea (23%), which were grade 1 or 2 in severity. Week 48 virologic response rates (% with VL <50 HIV-1 RNA copies/ml; Snapshot analysis) were 81% overall and 83% in treatment-naïve patients; median increases in CD4+ count at 48 weeks were 167 and 169 cells/mm³, respectively. Of 15/313 patients who met the criteria for resistance analysis, one developed a darunavir RAM as a mixture with wild-type (I84I/V), without phenotypic resistance to darunavir. The mean population pharmacokinetic-derived darunavir areas under the plasma concentration-time curve were 102,000 overall and 100,620 ng⋅h/ml in treatment-naïve patients. No clinically relevant relationships were seen between darunavir exposure and virologic response, AEs or laboratory parameters. Conclusion Darunavir/cobicistat 800/150 mg once daily was generally well tolerated through Week 48, with no new safety concerns. Pharmacokinetics, virologic and immunologic responses for darunavir/cobicistat were similar to previous data for darunavir/ritonavir 800/100 mg once daily.


Related Articles

  • Elvitegravir–Cobicistat–Emtricitabine–Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis. Gantner, Pierre; Hessamfar, Mojgan; Souala, Mohamed Faouzi; Valin, Nadia; Simon, Anne; Ajana, Faiza; Bouvet, Elisabeth; Rouveix, Elisabeth; Cotte, Laurent; Bani-Sadr, Firouzé; Hustache-Mathieu, Laurent; Lebrette, Marie-Gisèle; Truchetet, François; Galempoix, Jean-Marie; Piroth, Lionel; Pellissier, Gérard; Muret, Patrice; Rey, David; Group, E/C/F/TAF PEP Study // Clinical Infectious Diseases;3/1/2020, Vol. 70 Issue 5, p943 

    We evaluated an elvitegravir–cobicistat–emtricitabine–tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We...

  • Adherence to combination antiretroviral therapies in HIV patients of low health literacy. Kalichman, Seth C.; Ramachandran, Bineetha; Catz, Sheryl; Kalichman, S C; Ramachandran, B; Catz, S // JGIM: Journal of General Internal Medicine;May1999, Vol. 14 Issue 5, p267 

    Objective: To test the significance of health literacy relative to other predictors of adherence to treatment for HIV and AIDS.Participants: Community sample of HIV-seropositive men (n = 138) and women (n = 44) currently taking a triple-drug combination of...

  • Recurrent hypersensitivity to Combivir. Winston, Alan; McLean, Ken // International Journal of STD & AIDS;Mar2002, Vol. 13 Issue 3, p213 

    The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly used in combination antiretroviral therapy and are associated with hypersensitivity reactions on induction therapy. We report a case of recurrent hypersensitivity associated with Combivir, when there was a delay in...

  • Dolutegravir approved for HIV.  // WHO Drug Information;2013, Vol. 27 Issue 4, p361 

    The article discusses the recommendation by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) to grant a marketing authorization for dolutegravir (Tivicay) in combination with other antiretroviral medicines for HIV treatment of adults and adolescents over 12 years.

  • When should we delay highly active antiretroviral therapy? Bangsberg, David R.; Moss, Andrew; Bangsberg, D R; Moss, A // JGIM: Journal of General Internal Medicine;Jul1999, Vol. 14 Issue 7, p446 

    Focuses on the concern about the proper initiation of highly active antiretroviral therapy (HAART) in HIV-infected patients in the United States. Problems with patient adherence to HAART; Accounts on adherence as predictor of antiretroviral success; Relationship between adherence and viral...

  • Contribution of Genetic Background and Data Collection on Adverse Events of Anti–human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate Dietrich, Léna G; Barceló, Catalina; Thorball, Christian W; Ryom, Lene; Burkhalter, Felix; Hasse, Barbara; Furrer, Hansjakob; Weisser, Maja; Steffen, Ana; Bernasconi, Enos; Cavassini, Matthias; Seigneux, Sophie de; Csajka, Chantal; Fellay, Jacques; Ledergerber, Bruno; Tarr, Philip E // Clinical Infectious Diseases;3/1/2020, Vol. 70 Issue 5, p890 

    Background In human immunodeficiency virus (HIV), the relative contribution of genetic background, clinical risk factors, and antiretrovirals to chronic kidney disease (CKD) is unknown. Methods We applied a case-control design and performed genome-wide genotyping in white Swiss HIV Cohort...

  • Successful introduction of artesunate combination therapy is not enough to fight malaria: results from an adherence study in Sierra Leone Gerstl, Sibylle; Dunkley, Sophie; Mukhtar, Ahmed; Baker, Samuel; Maikere, Jacob // Transactions of the Royal Society of Tropical Medicine & Hygiene;May2010, Vol. 104 Issue 5, p328 

    Abstract: A study to measure adherence to artesunate and amodiaquine (AS+AQ) therapy in patients treated for uncomplicated malaria in community health centres (CHC) was conducted in Sierra Leone. Patients/caretakers were interviewed and remaining AS+AQ tablets at home after the last treatment...

  • Pharmacokinetic Optimization of Antiretroviral Therapy in Pregnancy. Buckoreelall, Kajal; Cressey, Tim R.; King, Jennifer R. // Clinical Pharmacokinetics;2012, Vol. 51 Issue 10, p639 

    Antiretroviral therapy suppresses replication of HIV allowing restoration and/or preservation of the immune system. Providing combination antiretroviral therapy during pregnancy can treat maternal HIV infection and/or reduce perinatal HIV transmission. However, providing treatment to pregnant...

  • New protease inhibitor offers flexible dosing.  // Drug Topics;11/3/2003, Vol. 147 Issue 21, p10 

    Reports on the approval of the U.S. Food and Drug Administration for fosamprenavir, a protease inhibitor for the treatment of HIV infections in adults in combination with other antiretroviral agents. Provision of flexible dosing by the drug; Citation of side effects associated with the product.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics